双重打击淋巴瘤治疗研究进展  

Advances in treatment of double-hit lymphoma

作　　者：张芳文[1] 李玲[1] 冯晓燕 李兆明[1] 张明智[1] Zhang Fangwen;Li Ling;Feng Xiaoyan;Li Zhaoming;Zhang Mingzhi(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Lymphoma Diagnosis and Treatment Centre of Henan Province,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院肿瘤科河南省淋巴瘤诊疗中心,450052

出　　处：《白血病．淋巴瘤》2018年第11期700-704,共5页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金(81570204);河南省医学科技攻关计划省部共建项目(201701009).

摘　　要：高级别B细胞淋巴瘤在2016年世界卫生组织淋巴瘤分类中被定义为一种独立的疾病,包括伴有myc和bcl-2或bcl-6基因重排的双重打击高级别B细胞淋巴瘤和不伴有myc和bcl-2或bcl-6基因重排的高级别B细胞淋巴瘤非特指型,均具有侵袭性的临床特点。双重打击淋巴瘤(DHL)具有相对独特的临床特点和不良预后,尽管高强度化疗可延长患者的生存期,但现有治疗方案疗效不佳,尚需特异性靶向药物精准治疗,信号通路抑制剂单药或联合治疗可改善患者不良预后。文章就DHL的定义、诊断、预后及最新的治疗进展加以综述。High grade B-cell lymphoma was defined as an independent disease in the 2016 new version of the World Health Organization lymphoma classification,including double-hit high grade B-cell lymphoma with myc and bcl-2 or bcl-6 gene rearrangements and high grade B-cell lymphoma,not otherwise specified without myc and bcl-2 or bcl-6 gene rearrangements,both of them are invasive in clinical features. In recent years,there have many studies on it,double-hit lymphoma (DHL)has relatively unique clinical features and poor prognosis.Although high-intensity chemotherapy can prolong the survival of patients,current treatment options have poor efficacy,and specific targeted drug therapies are still required.Single-agent or combination therapy of signal pathway inhibitors can improve the poor prognosis of patients.Immunotherapy is expected to become the direction of future research.This article reviews the definition,diagnosis,prognosis, and latest treatment progress of DHL.

关 键 词：淋巴瘤 B细胞 双重打击淋巴瘤 诊断 治疗 预后 

分 类 号：R733.1[医药卫生—肿瘤]